Feb 09,2024

Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results

Embecta, a global diabetes care company, reported its financial results for the quarter ending December 31, 2023. Embecta transitioned about 60% of its revenue to its own ERP system and made progress on regulatory filings, including a 510(k) filing for an open-loop insulin delivery system with the FDA. The revenues of the Company increased by 0.6% to $277.3 million, though it declined by 0.3% on a constant currency basis. U.S. revenues fell by 0.5%, while international revenues grew by 1.8% reported. Cash and equivalents were $298.7 million, with debt totaling $1.633 billion.

View Analyst & Ambassador Comments
Go to original news
Jul 30,2024

DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th

DarioHealth announced that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

View Analyst & Ambassador Comments
Go to original news
Apr 23,2024

Clinical ink announces GlucoseReady™

Clinical Ink has launched GlucoseReady, a comprehensive digital platform for cardiometabolic clinical trials. This GCP-compliant platform includes tools for electronic clinical outcomes (eCOA), behavioral assessments, lifestyle tracking, blood glucose monitoring (BGM), continuous glucose monitoring (CGM), digital weight scales, and actigraphy. It features unique capabilities such as triggering hypoglycemia eCOA based on BGM and CGM data and tools for tracking and preventing non-compliance. The platform is designed for therapeutic areas like diabetes, weight management, and NASH/MASH, aiming to enhance patient retention and provide real-time data visualization for sponsors.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jul 25,2024

Merdury signs MOU with Health2Sync to conduct trial of Merdury's StackDose technology intended for usage in GLP-1 (semaglutide) medication

Merdury Biopharmaceutical Corporation has signed a Memorandum of Understanding with Health2Sync to conduct clinical trials for Merdury's StackDose™ technology, aimed at enhancing the pharmacokinetic profile of oral semaglutide, a GLP-1 agonist used for diabetes and obesity treatment. Pre-clinical trials have shown that StackDose significantly improves semaglutide's absorption and bioavailability, resulting in prolonged blood concentration and extended duration of action. The collaboration will utilize Health2Sync's platform to streamline clinical trials, integrating continuous glucose monitoring data. "We're thrilled to partner with Merdury and leverage Health2Sync's platform to advance their innovative drug delivery technology," said Ed Deng, Co-founder and CEO of Health2Sync. "This collaboration underscores our commitment to empowering life sciences companies with the tools they need to accelerate clinical trials and deliver life-changing solutions to patients struggling with glucose control or weight management."

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Jul 25,2024

Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement

Eli Lilly will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 25,2024

Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

Dexcom reported robust financial results for the second quarter of 2024, with a 15% year-over-year revenue increase to $1.004 billion. U.S. revenue grew by 19%, while international revenue increased by 7%. The company achieved a GAAP operating income of $158 million and a non-GAAP operating income of $195.4 million. Significant strategic advancements during this quarter included the launch of Direct-to-Watch in the U.S. and international markets, expanded coverage for Dexcom ONE in France, and integration with new insulin delivery systems. Dexcom also updated its fiscal year 2024 guidance, projecting revenue between $4.00 and $4.05 billion and reaffirming other financial targets. Additionally, the company announced a $750 million share repurchase program.

View Analyst & Ambassador Comments
Go to original news
Jul 16,2024

Diabeloop study reveals significative sex differences in insulin requirements for Type 1 diabetes patients

A groundbreaking real-world study involving over 9,000 adults with type 1 diabetes has uncovered important differences between males and females in insulin requirements. The study, conducted across Europe, utilized data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop insulin delivery device and was published last month in the Journal of Diabetes Science and Technology. The study included 9,036 participants across multiple European countries, with women representing 59% of the cohort. The average study period was 320 days, amassing 2,887,188 days of data. 

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jul 16,2024

Dario Expands GLP-1 Solution Client Base with New Employer Contract

DarioHealth announced a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024. The employer selected Dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a GLP-1 medication.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Jul 11,2024

Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024

Tandem Diabetes Care plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Jul 08,2024

A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor

A new peer-reviewed study published by Know Labs in Diabetes Technology and Therapeutics Journal aimed to assess Know Labs' noninvasive blood glucose measurement method for classifying glycemic status using a novel radiofrequency (RF) glucose sensor combined with machine learning. Data were collected from 31 participants with prediabetes or type 2 diabetes using both the RF sensor and traditional glucose meters. The results showed that the machine learning model achieved an overall accuracy of 93.37% in classifying glycemic status. Specifically, the model demonstrated sensitivities of 85.51% for hyperglycemic, 96.63% for normoglycemic, and 50.00% for hypoglycemic statuses. The specificities were 96.92% for hyperglycemic, 84.51% for normoglycemic, and 99.81% for hypoglycemic statuses. These findings suggest that the RF sensor, in conjunction with machine learning, can effectively classify glycemic status, indicating its potential for noninvasive diabetes screening.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES